A hi-tech boom helps the medicine go down

Injections without needles, pills with microchips - drug delivery systems are a rapidly growing secto

Faced with the prospect of having a needle jabbed into their private parts, most men would politely decline, but until recently such an injection has been the most effective way to cure male impotence.

Then Vivus, a US drug delivery company, found an alternative - packaging the same drug into pellets to be delicately inserted into the urethra - and took half the $60m world market in four months.

The next improvement could come from PowderJect, which will float on the London stock market this month and has a pain-free, needle-less injection. "If all men suffering from impotence had treatment, this would be a $500m market," says Paul Drayson, PowderJect's chairman.

As this example shows starkly, the way a drug is given can matter at least as much as what it does. This is the premise behind the drug delivery industry. The sector has come from nowhere 10 years ago, to capture a $12bn slice of the $150bn world-wide pharmaceutical market. Moreover drug delivery is growing fast - at 15-20 per cent a year, twice as fast as the wider drugs market.

The product that put drug delivery on the map was a heart pill called Procardia XL. The first version of Procardia, sold by Pfizer, had to be swallowed three times a day, restricting sales to $400m a year, and in 1989 was about to lose its patent.

In a well-timed move, Pfizer linked up with Alza - a then tiny drug delivery company - which came up with a once-a-day version, reviving Procardia's patent and tripling sales to $1.2bn. Felix Theeuwes, Alza's president of research and development, remembers the excitement: "We enormously expanded the market for angina drugs. Our technology gave Pfizer its first billion-dollar drug."

The range of delivery technologies today is vast and ingenious. It includes everything from simple skin patches, inhalers, gels and nasal sprays to implants, pills with microchips and contact lenses that release drugs into the eye.

SkyePharma's Geomatrix technology, for example, can release a drug in tablet form immediately, slowly over days or in prescribed bursts so that, say, someone at risk of heart attack could take a pill before bed and get regular doses throughout the night. Elan is developing a smart pill embedded with a microchip and Alza has a titanium implant, no bigger than a matchstick, that leaks out a cancer drug over a year.

The most exciting area in delivery, though, is driven by the biotechnology industry, which is developing protein and peptide-based compounds like insulin. These large and complex molecules have to be given by injection because they are digested if swallowed and are too big to pass normally through the skin.

Among the many companies working in this area, Cortecs is developing insulin and brittle bone pills, Inhale has an insulin dry powder inhaler and PowderJect a helium pump which can drive molecules through the skin at three times the speed of sound.

For both patients and healthcare payers, there are huge benefits in all this - the easier a drug is to take, the more compliant a patient will be. Alex Zisson of US broker Hambrecht & Quist says the cost benefits of improving compliance are central to the delivery sector: "In the US, 28 per cent of hospital admissions can be traced to people not taking their drugs properly."

Glen Travers, chairman of Cortecs, says that less than a third of women prescribed hormone patches for brittle bones stay on the treatment after two years: "The cost to the US government in hospital fees to treat broken bones is $10bn a year and growing."

For the big pharmaceutical companies, meanwhile, a clever delivery system can extend the patent life of their drugs, generating substantial extra revenues. The number of alliances with specialist delivery companies is growing.

Alza's Mr Theeuwes says: "It is financially unrewarding for pharma groups to spend millions on their own technologies to improve just one drug." Donal Geaney, president of Elan, says: "Many medicines stay on the shelf because they cannot be delivered properly and this is costly."

Rolf Stahel, chief executive of Shire, sees another reason for alliances: "Research directors in big pharma groups are not enthusiastic about delivery. It does not lead to Nobel prizewinners."

Investors, though, should be more excited. While the small numbers of UK delivery companies are normally lumped in with their biotechnology cousins, as Jo Walton of broker Lehman Brothers points out, their risk profiles are substantially different.

"Delivery companies work on existing chemicals, where all the data - animal tests, safety, which patients to target, which clinical trials to use - are already known. Times to market are shorter and the chances of success are higher." Mr Zisson agrees: "It takes a delivery company about three to four years to get a drug to market, compared to six years for a normal drug."

Financial risks are also lower. Robert Chess, chief executive of Inhale, estimates his research costs are a tenth those of an average biotech company and with three times as many products, risks are spread.

And as Richard Stewart, SkyePharma's finance director, points out, the development costs of reformulating an old drug are borne by clients, while established sales and marketing teams can push the new version at minimal cost: "All this means more in royalties," he says.

Though royalties can limit upside, companies working in protein delivery or on big drugs stand to gain substantial returns and make profits sooner than most biotechs. So far, their potential is more apparent in the US. According to Ms Walton: "Investors are more cynical in the UK, where hopefuls like Cortecs have not yet made it. In the US there are some huge and profitable companies." UK delivery companies may not be far behind.

Drug delivery contenders

Company Market value

Alza Corp (US) $2.5bn

Cortecs (UK) pounds 277m

Cygnus $292m

Dura Pharmacls (US) $1.7bn

Elan Corp (Irish/US) pounds 2.5bn

Ethical Holdings (US/UK) $78m

Guilford Pharmacls $501m

Inhale (US) $307m

Liposome Company (US) $993m

PowderJect (UK) pounds 109m

RP Scherer $1.3bn

Shire Pharmacls (UK) pounds 198m

SkyePharma (UK) pounds 307m

TheraTech (US) $237m

Vivus (US) $13m

PROMOTED VIDEO
News
ebookA unique anthology of reporting and analysis of a crucial period of history
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

BA/PM,EMIR/Dodd-Frank,London,£450-650P/D

£450 - £650 per day + competitive: Orgtel: My client, a leading bank, is curre...

Senior Analyst - ALM Data - Banking - Halifax

£350 - £400 per day + competitive: Orgtel: Senior Analyst, ALM Data, Halifax, ...

Java developer - Banking - London - Up to £600/day

£500 - £600 per day: Orgtel: Java developer - Banking - London - Up to £600/d...

Liquidity Reporting-Basel III-LCR-Bank-£400/day

£400 per day + competitive: Orgtel: Liquidity Reporting - Basel III - LCR - Ba...

Day In a Page

Save the tiger: The animals bred for bones on China’s tiger farms

The animals bred for bones on China’s tiger farms

The big cats kept in captivity to perform for paying audiences and then, when dead, their bodies used to fortify wine
A former custard factory, a Midlands bog and a Leeds cemetery all included in top 50 hidden spots in the UK

A former custard factory, a Midlands bog and a Leeds cemetery

Introducing the top 50 hidden spots in Britain
Ebola epidemic: Plagued by fear

Ebola epidemic: Plagued by fear

How a disease that has claimed fewer than 2,000 victims in its history has earned a place in the darkest corner of the public's imagination
Chris Pratt: From 'Parks and Recreation' to 'Guardians of the Galaxy'

From 'Parks and Recreation' to 'Guardians of the Galaxy'

He was homeless in Hawaii when he got his big break. Now the comic actor Chris Pratt is Hollywood's new favourite action star
How live cinema screenings can boost arts audiences

How live cinema screenings can boost arts audiences

Broadcasting plays and exhibitions to cinemas is a sure-fire box office smash
Shipping container hotels: Pop-up hotels filling a niche

Pop-up hotels filling a niche

Spending the night in a shipping container doesn't sound appealing, but these mobile crash pads are popping up at the summer's biggest events
Native American headdresses are not fashion accessories

Feather dust-up

A Canadian festival has banned Native American headwear. Haven't we been here before?
Boris Johnson's war on diesel

Boris Johnson's war on diesel

11m cars here run on diesel. It's seen as a greener alternative to unleaded petrol. So why is London's mayor on a crusade against the black pump?
5 best waterproof cameras

Splash and flash: 5 best waterproof cameras

Don't let water stop you taking snaps with one of these machines that will take you from the sand to meters deep
Louis van Gaal interview: Manchester United manager discusses tactics and rebuilding after the David Moyes era

Louis van Gaal interview

Manchester United manager discusses tactics and rebuilding after the David Moyes era
Will Gore: The goodwill shown by fans towards Alastair Cook will evaporate rapidly if India win the series

Will Gore: Outside Edge

The goodwill shown by fans towards Alastair Cook will evaporate rapidly if India win the series
The children were playing in the street with toy guns. The air strikes were tragically real

The air strikes were tragically real

The children were playing in the street with toy guns
Boozy, ignorant, intolerant, but very polite – The British, as others see us

Britain as others see us

Boozy, ignorant, intolerant, but very polite
How did our legends really begin?

How did our legends really begin?

Applying the theory of evolution to the world's many mythologies
Watch out: Lambrusco is back on the menu

Lambrusco is back on the menu

Naff Seventies corner-shop staple is this year's Aperol Spritz